Small Molecule Compound definition

Small Molecule Compound means a small molecule compound [*] or [*]. For clarity, [*], shall be considered Small Molecule Compounds.
Sample 1Sample 2
Small Molecule Compound means a molecule with a molecular weight less than or equal to [ * ].
Sample 1Sample 2Sample 3
Small Molecule Compound shall have the meaning set forth in the definition of Compound.
Sample 1Sample 2Sample 3

Examples of Small Molecule Compound in a sentence

  • Subject to the terms and conditions of this Agreement, in the event that Genentech elects not to develop a Small Molecule Compound, pursuant to this Section 3.1.3, or if after electing to develop such a Small Molecule Compound, ceases development, [**].

  • In such case, any Small Molecule Compound selected for Development in accordance with the terms of such definitive agreement that is not a Back-up Product under the terms of such definitive agreement shall be deemed to be a Collaboration Product for purposes of Sections 11.3 and 11.4 if (y) [**] or (z) [**].

  • Milestone payments made by Genentech for Small Molecule Compound(s) never reaching a Regulatory Approval are fully creditable back to Genentech at the time of Small Molecule Product or Small Molecule Compound withdrawal from the Collaboration Program.

  • For clarity, the licenses granted in Section 7.1 by Exelixis to BMS do not give BMS any right or license (a) to incorporate into any Product (e.g., as a combination product) any compound that is Controlled by Exelixis and that is not a Licensed Compound or (b) to perform any research that is directed to identifying, characterizing, developing or otherwise pursuing any Small Molecule Compound that is not a Licensed Compound.

  • In the event that a party is presented with a Third Party Opportunity for the development and commercialization of a Small Molecule Compound acting through a Selected Target that has been previously designated as an Inactive Selected Target, a BMS Target or a Lexicon Target, then the party may pursue such Third Party Opportunity, but only in the manner provided in this Section 2.11.2 and subject to the parties' obligations under Section 2.6.1(b) and Article 8.

  • In the event that a Small Molecule Compound or Small Molecule Product shall fail to achieve Regulatory Approval in any country ("Failed Compound"), such milestone amount paid shall be applied to any future Compound or Product put into development by the Joint Project Team ("Replacement Compound").

  • In the event that a party is presented with an opportunity to obtain a license from a Third Party for the development and commercialization of a Small Molecule Compound acting through a Selected Target (a "Third Party Opportunity"), then the party may pursue such Third Party Opportunity, but only in the manner provided in this Section 2.11.

  • If a Party becomes aware of any actual or potential claim that the research, Development, Manufacture or Commercialization of any Target, Protein Therapeutic or Small Molecule Compound being researched, Developed, Manufactured or Commercialized pursuant to this Agreement, a Development & Commercialization Agreement or the [***]SM Agreement, infringes the intellectual property rights of any Third Party, such Party shall promptly notify the other Party.

  • Regulatory Approval Regulatory Authority Regulatory Materials Research Resulting Patents ROW Territory Small Molecule Compound Specifically Directed Sublicensee Target Territory Third Party Third Party License [***] [***] Program [***] Option Exercise Notice [***] Program United States or U.S. Valid Claim [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.

  • Lexicon hereby obtains exclusive rights under Section 4.1.2.3 and Section 4.2.2 with respect to the LG921 Target and, accordingly, (i) the LG921 Target is hereby designated as a “Lexicon Target,” (b) Lexicon is hereby the Product Licensee with respect to the LG921 Target and (c) the exclusive licenses granted to Lexicon under Section 4.1.2.3 and Section 4.2.2 (including, without limitation, with respect to the Small Molecule Compound designated by BMS as [**]) shall apply to the LG921 Target.


More Definitions of Small Molecule Compound

Small Molecule Compound means any molecule that has a molecular weight [ * ].
Sample 1Sample 2Sample 3
Small Molecule Compound means a composition comprising a chemical compound, whether synthetic or naturally-derived, that is not an Antibody, an Antisense Compound or a Protein.
Sample 1
Small Molecule Compound means a chemical compound having a molecular weight of less than 1,000 Daltons, [**]. For clarity, Small Molecule Compound specifically excludes any compound that consists of or incorporates as an active ingredient [**] (a) a protein, (b) an antibody or any fragment thereof, (c) an antisense product or (d) an oligonucleotide.
Sample 1
Small Molecule Compound means a chemical compound having a molecular weight of less than 1,000 Daltons, as well as conjugates of such chemical compounds to larger molecules to improve the delivery, bioavailability and/or pharmacokinetic properties of such chemical compound. For clarity, Small Molecule Compound specifically excludes any compound that consists of or incorporates as an active ingredient (i.e., other than to affect the delivery, bioavailability and/or pharmacokinetic properties of the compound) (a) a protein, (b) an antibody or any fragment thereof, (c) an antisense product or (d) an oligonucleotide.
Sample 1
Small Molecule Compound means any organic, non-peptidic (meaning with maximum four amino acids) Compound with a molecular weight below 800 Daltons, including any salt, amorphous, crystalline, solvate, ester, ether, and/or stereo-isomeric variation thereof, for which Evotec has conducted the drug discovery efforts under the Collaboration Activities as per the JSC’s decision.
Sample 1

Related to Small Molecule Compound

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Licensed Compound means (a) 3,4-Diaminopyridine, the chemical structure of which is set forth on Exhibit B-2; and (b) any derivatives, isomers, metabolites, prodrugs, acid forms, base forms, salt forms, or modified versions of such compound in (a).

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.

  • Compound means the taking of two or more ingredients and fabricating them into a single

  • Licensed Compounds means any EZH2 Compound(s) that is:

  • Back-Up Compound means, with reference to any particular Development Candidate or Drug Product Candidate, a Compound which (a) has the same principal mode of action (i.e., Potentiator or Corrector) as that Development Candidate or Drug Product Candidate; and (b) was among the group of Compounds, identified by VERTEX as potential additional lead molecules having the same principal mode of action, from which the Development Candidate was selected.

  • Product Candidate means each of MYO-101, MYO-102, MYO-103, MYO-201 and MYO-301, as defined on Exhibit B, in each case in any form or formulation.

  • Development Candidate means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.

  • Compounds means a small molecule HMT inhibitor.

  • Diagnostic Product means In Vitro Diagnostics, In Vivo Diagnostic Agents and any product used for Diagnosis.

  • Exempt compound means the same as defined in Rule 2.

  • Collaboration Product means a pharmaceutical product containing or comprising Compound in any dosage form alone, or in combination with, one or more other pharmaceutically active ingredients, and any and all Improvements thereto.

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Hemp product means the same as that term is defined in § 3.2-4112.

  • Licensed Product means any method, process, composition, product, service, or component part thereof that would, but for the granting of the rights set forth in this Agreement, infringe a Valid Claim contained in the Licensed Patents.

  • Phase IIb Clinical Trial means a clinical trial of a Product on sufficient numbers of patients that is designed to provide a preliminary determination of safety and efficacy of such Product in the target patient population over a range of doses and dose regimens.

  • Drug Product means a specific drug in dosage form from a known source of manufacture, whether

  • Phase I Clinical Study means, as to a particular Licensed Product, an initial clinical study in humans with the purpose of assessing the Licensed Product’s safety, tolerability, toxicity, pharmacokinetics or other pharmacological properties.

  • Antibody means a molecule or a gene encoding such a molecule comprising or containing one or more immunoglobulin variable domains or parts of such domains or any existing or future fragments, variants, modifications or derivatives thereof.

  • Phase I Clinical Trial means a study in humans which provides for the first introduction into humans of a product, conducted in normal volunteers or patients to generate information on product safety, tolerability, pharmacological activity or pharmacokinetics, or otherwise consistent with the requirements of U.S. 21 C.F.R. §312.21(a) or its foreign equivalents.

  • Biological Samples means any physical samples obtained from Study Participants in accordance with the Protocol for the purposes of the Study.

  • Phase III Clinical Study means a trial involving administration of a Compound to sufficient numbers of human patients with the goal of establishing that the Compound is safe and efficacious for its intended use, to define warnings, precautions and adverse reactions that are associated with the drug or label expansion of such Compound, and to be considered as a pivotal study for submission of an NDA.

  • Phase II Clinical Study means a human clinical study of a product initiated to determine the safety and efficacy in the target patient population, as described 21 C.F.R. 312.21(b).

  • Phase III Clinical Trials means a Clinical Trial for the Product on sufficient numbers of patients to generate safety and efficacy data to support Regulatory Approval in the proposed therapeutic indication, conducted in accordance with current good clinical practices and in accordance with a protocol that has been reviewed by the FDA and reflects any comments or concerns raised by the same.

  • Phase II Clinical Trial means a controlled human clinical study that would satisfy the requirements of 21 CFR 312.21(b), conducted to study the effectiveness and establish the dose range of a Product for a particular Indication in patients with the disease or condition under study, including a Phase IIA Clinical Study or Phase IIB Clinical Study.

  • Combination Product means (a) a product containing a Licensed Product together with one or more other active ingredients that have independent biologic or chemical activity when present alone that are sold as a single unit, or (b) a Licensed Product together with one or more products, devices, pieces of equipment or components thereof, that are sold as a single package at a single price.